BEThe pharmaceutical company GlaxoSmithKline (GSK) plans to cut over 1,200 jobs as part of a restructuring effort, which has drawn criticism from Solidaris and Setca, two Belgian organizations representing healthcare and workers' interests. They argue that this decision reflects a broader trend in the pharmaceutical industry where companies prioritize highly profitable treatments, particularly in oncology, at the expense of other areas of their operations. The groups criticize GSK’s decision despite the company’s significant profits, including €2.4 billion in net income from its vaccines division in 2025, along with substantial public funding and reimbursements from the national health system. Solidaris and Setca claim that the high prices of cancer treatments give pharmaceutical firms excessive power in price negotiations, forcing governments to comply with costly reimbursement demands. They call for stronger regulation to ensure fair pricing and prevent job losses in the healthcare sector.
Lecture du biais (Progressiste): The article frames the restructuring at GSK as a consequence of 'a race for excessive profits,' emphasizing the negative impact on employment and public healthcare. It criticizes the pharmaceutical industry for prioritizing profit over public interest and calls for government intervention to set 'fa
